Page 23 - Read Online

Hafezi et al. Hepatoma Res 2018;4:16 I http://dx.doi.org/10.20517/2394-5079.2018.55 Page 7 of 8

REFERENCES
1. Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol
2018;19:222-32.
2. Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009;49:S13-21.
3. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582-92.
4. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 2004;350:1118-29.
5. Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol 2014;20:4115-
27.
6. Mlynarsky L, Menachem Y, Shibolet O. Treatment of hepatocellular carcinoma: steps forward but still a long way to go. World J Hepatol
2015;7:566-74.
7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C,
Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J;
SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
8. Lee SG. Living-donor liver transplantation in adults. Br Med Bull 2010;94:33-48.
9. Saab S, Yeganeh M, Nguyen K, Durazo F, Han S, Yersiz H, Farmer DG, Goldstein LI, Tong MJ, Busuttil RW. Recurrence of hepatocellular
carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl 2009;15:1525-
34.
10. Lee JO, Kim DY, Lim JH, Seo MD, Yi HG, Oh DY, Im SA, Kim TY, Bang YJ. Palliative chemotherapy for patients with recurrent
hepatocellular carcinoma after liver transplantation. J Gastroenterol Hepatol 2009;24:800-5.
11. Rahimi RS, Trotter JF. Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence. Ann Gastroenterol
2015;28:323-30.
12. Pardee AD, Butterfield LH. Immunotherapy of hepatocellular carcinoma: unique challenges and clinical opportunities. Oncoimmunology
2012;1:48-55.
13. Breous E, Thimme R. Potential of immunotherapy for hepatocellular carcinoma. J Hepatol 2011;54:830-4.
14. Bertoletti A, Bert NL. Immunotherapy for chronic hepatitis B virus infection. Gut Liver 2018; doi: 10.5009/gnl17233.
15. Wan S, Kuo N, Kryczek I, Zou W, Welling TH. Myeloid cells in hepatocellular carcinoma. Hepatology 2015;62:1304-12.
16. Kahan SM, Wherry EJ, Zajac AJ. T cell exhaustion during persistent viral infections. Virology 2015;479-480:180-93.
17. Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, Yamazaki T, Poirier-Colame V, Newton A, Redouane Y, Lin
YJ, Wojtkiewicz G, Iwamoto Y, Mino-Kenudson M, Huynh TG, Hynes RO, Freeman GJ, Kroemer G, Zitvogel L, Weissleder R, Pittet MJ.
Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 2016;44:343-54.
18. Vonderheide RH. The immune revolution: a case for priming, not checkpoint. Cancer Cell 2018;33:563-9.
19. Villanueva A, Llovet JM. Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma.
Hepatology 2012;56:2416-9.
20. Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 2015;75:2139-45.
21. Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.
Nat Rev Endocrinol 2017;13:195-207.
22. Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer 2017;123:1904-11.
23. Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J. Acute renal allograft rejection after immune checkpoint inhibitor
therapy for metastatic melanoma. Ann Oncol 2016;27:1135-7.
24. Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer. Cell Res 2017;27:38-58.
25. Sadelain M, Riviere I, Riddell S. Therapeutic T cell engineering. Nature 2017;545:423-31.
26. D’Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. CAR-T cells: the long and winding road to solid tumors. Cell Death Dis
2018;9:282.
27. Chmielewski M, Hombach AA, Abken H. Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-
redirected T cells. Front Immunol 2013;4:371.
28. Li K, Lan Y, Wang J, Liu L. Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles. Tumour Biol
2017;39:1010428317692229.
29. Garber K. Driving T-cell immunotherapy to solid tumors. Nat Biotechnol 2018;36:215-9.
30. Barrett DM, Grupp SA, June CH. Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street. J Immunol
2015;195:755-61.
31. Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 2013;31:999-1008.
32. Bertoletti A, Brunetto M, Maini MK, Bonino F, Qasim W, Stauss H. T cell receptor-therapy in HBV-related hepatocellularcar cinoma.
Oncoimmunology 2015;4:e1008354.
33. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69-74.
34. The problem with neoantigen prediction. Nat Biotechnol 2017;35:97.
35. Bertoletti A, Tan AT, Koh S. T-cell therapy for chronic viral hepatitis. Cytotherapy 2017;19:1317-24.
36. Tu T, Budzinska MA, Shackel NA, Urban S. HBV DNA integration: molecular mechanisms and clinical implications. Viruses 2017;9:E75.
37. Eshhar Z. Tumor-specific T-bodies: towards clinical application. Cancer Immunol Immunother 1997;45:131-6.
38. Kruse RL, Shum T, Tashiro H, Barzi M, Yi Z, Whitten-Bauer C, Legras X, Bissig-Choisat B, Garaigorta U, Gottschalk S, Bissig KD.
HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice. Cytotherapy 2018;20:697-705.
39. Gehring AJ, Xue SA, Ho ZZ, Teoh D, Ruedl C, Chia A, Koh S, Lim SG, Maini MK, Stauss H, Bertoletti A. Engineering virus-specific T
cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol 2011;55:103-10.